Drilldown: Medicines

Other values:

Search

None (87) · COMP360 (Compass Pathways, investigational synthesized clinical formulation) (1) · Delysid (historical, Sandoz, withdrawn 1965) (1) · DXM (1) · DXO (1) · Spravato (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antipsychotic · Antiparkinsonian · Empathogen · Neuroleptic · Cathinone

Other values:

Search

5-HT2A agonist (26) · Potent 5-HT2A agonist (5) · LSD analogue; 5-HT2A agonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · NMDA antagonist (3) · Contains LSA (2) · Contains mescaline (2) · NMDA antagonist; sigma receptor agonist (2)

Other values:

Search

None (90) · (investigational) '"`UNIQ--vote-000000EF-QINU`"', '"`UNIQ--vote-000000F0-QINU`"', '"`UNIQ--vote-000000F1-QINU`"', '"`UNIQ--vote-000000F2-QINU`"', '"`UNIQ--vote-000000F3-QINU`"' (1) · Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1)

None (90) · Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1) · Modern clinical-trial standard: 25 mg synthesized psilocybin, single oral dose with psychological support (1)

None (90) · 28 mg/device (each dose uses 2 devices) (1) · Synthesized psilocybin capsules (COMP360 and other investigational formulations); dried whole [[Psilocybe|Psilocybe]] mushrooms (variable potency, no legal supply chain in most jurisdictions); psilocybin truffles (Psilocybe sclerotia, legal in the Netherlands) (1)

None (90) · 84 mg per session (1) · Not FDA-approved; clinical-trial protocols use up to 30 mg in adult investigational dosing (1)

None (89) · Intranasal (under direct medical supervision) (1) · Oral (2)

None (89) · 20-45 min subjective onset; psilocin formation from psilocybin requires intestinal and hepatic alkaline phosphatase (1) · 30–60 minutes (1) · Within hours of first administration (1)

None (88) · 4-6 hours (1) · 8–12 hours (1) · About 20 minutes (1) · Acute effect ~24 hours; cumulative effect builds with repeated dosing (1)

None (88) · 3–5 hours (1) · 9–12 minutes (intravenous) (1) · Psilocin: ~2-3 h; psilocybin itself is a prodrug, dephosphorylated within minutes of absorption (1) · ~7-12 hours (1)

None (89) · 70–90% (oral) (1) · Oral bioavailability of psilocin from administered psilocybin approximately 50% (1) · ~48% intranasal (1)

None (89) · Avoid; may cause fetal harm (1) · Not established (1) · Not studied in human pregnancy; no approved clinical use in any population (1)

None (89) · Rx, Schedule III (US). REMS program required. (1) · Schedule I (United States) (1) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1)